Dewpoint’s condensate platform works to target individual molecules and interacting groups of molecules within condensate communities to create new treatments for incurable and untreatable diseases.
Supplier News
Advertisement
Suitable for bioprocessing, solubilization, and stabilization applications, the new histidine products allow for the control of endotoxin and trace metal impurities reflected with elemental impurity data in parts per billion on their specifications.
The agreement will accelerate production of SiO2’s plastic vials for vaccines and therapeutics for Operation Warp Speed.
Stevanato Group’s Vision Robot Unit uses AI-based machine learning capabilities for particle and cosmetic inspection of biopharmaceutical drug products.
Through the acquisition, the companies plan to build a global science-based organization that uses product innovation to enhance ABITEC’s scientific and commercial interests.
The new SDMS automatically gathers and protects all instrument and other laboratory data as it is generated for enhanced lab management, quality, and security.
The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.
The company will manufacture a conjugated vaccine candidate being developed to prevent the disease melloidosis.
SGS has announced the receipt of approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) to begin a new clinical trial of a potential treatment for patients with COVID-19 related respiratory failure.
The European Commission has approved Lynparza (olaparib) for use in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer within the European Union.
Advertisement
GlaxoSmithKline (GSK) and Medicago have announced a collaboration for the development and evaluation of a COVID-19 vaccine candidate.
The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.
Emergent is entering into a five-year agreement with Janssen Pharmaceuticals for the large-scale drug substance manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S.
The agreement will combine Rentschler’s experience in drug substance manufacturing and Vetter’s expertise in aseptic fill/finish and secondary packaging.
The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.
Aji Bio-Pharma launched Ajility, a flexible platform for manufacturing vaccines and therapies.
The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.
The expansion included adding new softgel encapsulation lines at its Strathroy, Canada and Sorocaba, Brazil sites for Catalent’s Vegicaps plant-based capsule and its CosmoPod twist-off capsule technologies.
The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing.
Enhanced sensitivity and ultra-high detection speed provide improved robustness and operability.
Pall has introduced a 24-well filter plate that can perform cell clarification and sterilization in one step.
The company has provided updates on its COVID-19 tests under development with Adeptrix and Cytiva, respectively.
The refurbishment provides enhanced glass melting power, improved glass distribution, and the production of transparent and amber type I glass bottles to meet the increase in demand for glass vials for vaccines and life-saving medicines.
Honeywell Forge Cybersecurity Suite’s improved industrial-grade remote access and added protection and risk monitoring aids remote operations.
The partnership combines Malvern’s physicochemical characterization expertise and Concept Life Sciences’ chemistry and analytical services to provide services that focus on analytics, know-how, instrumentation, and expert support to customers.
The updated facility is 60,000 square feet and is equipped with bioprocessing capabilities ranging from 10L to 2000L.
Catalent will offer vial filling, packaging capacity, and additional staffing at the site to support the production of the initial 100 million doses of the vaccine candidate to supply the US market beginning in the third quarter of 2020.
The company has expanded its laboratory test portfolio with five new molecular, serology, and functional assays for COVID-19 vaccine and therapy development programs.
The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.
The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France.
Advertisement
Advertisement
